 |
|
|
| |
North American Phase 3/3b Experience With Long-Acting
Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes
|
| |
| |
Babafemi O. Taiwo1, Darrell H. S. Tan2, Parul Patel3, Paula Teichner3, Joseph W. Polli3, Louise Garside4, Ronald D'Amico3, Christine Talarico3,
Rodica Van Solingen-Ristea5, Bryan Baugh6, William R. Spreen3, Michael Aboud7, Matthew Bosse8
1Northwestern University, Chicago, IL, United States; 2St. Michael's Hospital, Toronto, ON, Canada; 3ViiV Healthcare, Research Triangle Park, NC, United States; 4GlaxoSmithKline, London, United Kingdom; 5Janssen Research & Development, Beerse, Belgium; 6Janssen Research & Development, Titusville, NJ, United States; 7ViiV Healthcare, Brentford, United Kingdom; 8ViiV Healthcare, San Diego, CA, United States
|
| |
|
|
|
|
|
